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INTRODUCTION 
Colorectal cancer (CRC) is the third most common 
cancer worldwide with an estimated number of 1.4 
million (9.7%) cases in the year 2012 (1). In Malaysia, 
2246 CRC cases (12.3%) were reported in 2011 (2). It 
is widely recognized that genetic factors such as 
inactivation of tumor suppressor genes (3-5), 
activation of oncogenes (6, 7), DNA–repair defects (8, 
9), aberrant DNA methylation (10, 11) and 
chromosomal instability (12-14) play important roles 
in the pathogenesis of CRC.  
 
However, avoiding immune destruction has now been 
recognized as an important hallmark in cancer 
progression (15). There is considerable evidence to 
suggest that the immune system plays a protective role 
in tumorigenesis (16-18). Although immune 
surveillance is responsible for the elimination of 
foreign antigens, the tumor cells, however, are able to 
manipulate and escape from host immune cell 
recognition. In addition, immune responses depend on 
the inheritance of highly polymorphic HLA genes in 
promoting the generation of T cells and B cells. The 
genetic polymorphisms, in turn, affect how the HLA 
presents the peptide and provide signals to the T cells. 
Theoretically, somatic alterations in tumor would not 
influence the expression of HLA class II gene in 
dendritic cells, macrophages and B lymphocytes (the 
antigen presenting cells) (18). However, it is argued 
that the HLA antigen processing pathway could be 
significantly altered as part of the tumorigenesis 
process (19, 20). Therefore, in many tumors, somatic 
alterations could indirectly contribute to the 
downregulation or upregulation of HLA gene 
expression (21). Furthermore, intrinsic modifications 
of various cellular compartments and components 
such as lipids and enzymes are likely to influence, 
either directly or indirectly, the processing, loading 
and presentation of antigen to T cells. Therefore the 
inheritance of certain allele(s) could affect the way the 
peptides are presented to T cells.  
 
Consequently, individuals who inherit specific alleles 
of highly polymorphic HLA class II DRB, DQB and 
DPB genes might be susceptible or resistant to specific 
types of cancers (17, 18, 22, 23).  In addition, loss of 
certain effector functions in HLA is often associated 
with susceptibility to particular types of cancers, 
suggesting that different malignancies are controlled 
by different immune effector mechanisms (24). Also, 
the peptides lodged in the antigen-binding grooves of 
specific HLA class II heterodimers may fail to activate 
the T cells and subsequently unable to produce the 
appropriate signals for cytokine release to activate the 
T cell response. It is likely that changes in the HLA 
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ABSTRACT 
 
Many studies have shown that the immune response highly depends on the inheritance of specific HLA 
genes in promoting the generation of T cells for the elimination of pathogens. Loss or alteration of HLA 
antigen expression in tumor cells has been observed in a variety of human malignancies leading to immune 
escape or immune resistance. We investigated whether the inheritance of certain alleles of HLA class II 
genes confers susceptibility or resistance towards the development of colorectal carcinoma (CRC). 
Molecular typing of HLA DRB1, DQB1 and DPB1 alleles in 42 patients diagnosed with CRC and 50 
ethnically matched healthy controls using the PCR-sequence based typing (PCR-SBT) was conducted. The 
HLA DPB1*02:01:02 was significantly higher in CRC patients (38.1%, p=0.0189) compared to healthy 
controls (16%). Also, HLA DQB1*05:02:01 was present in 28.6% of CRC patients but only 10% of healthy 
controls (p=0.0278). The odds ratios for HLA DPB1*02:01:02 and HLA DQB1*05:02:01were 3.23 and 3.60, 
respectively. There were no significant association observed for the DRB1 allele with CRC. Our study 
suggests that the HLA DPB1*02:01:02 and HLA DQB1*05:02:01 alleles may confer a higher risk for CRC. 
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class II expression may significantly influence tumor 
cell evasion of immune surveillance (16). In view of 
the association between HLA class II and CRC, 
changes in expression of HLA class II molecules in the 
CRC patients may have important implications for the 
presentation of tumor antigens to the T cell. 
During past 30 years, there are only a few studies on 
the association of HLA class II alleles with CRC. All 
of these studies emphasized on the frequency of HLA 
class II expression in CRC tissues which ranged from 
21% to 55% using the immunohistochemistry method 
(17, 25-27). The studies yielded mixed results, mostly 
due to confounding factors such as tumor type, origin, 
source and small sample size. As such, the prognostic 
value of HLA Class II expression is certainly not 
universal. Very limited information is available on 
HLA class II allele in CRC. In fact, the only study on 
HLA typing showed that patients with HLA-
DQB1*02 allele were more susceptible to early onset 
of CRC (mean age= 57.49±12.71) than those without 
(mean age 62.94±10.79)(28). Nevertheless, there are 
other studies on association HLA class II alleles with 
other types of cancer such as breast cancer, 
hepatocellular carcinoma, leukemia and cervical 
cancer (18, 22, 29-32). For example, HLA 
DQB*03032 and HLA DRB1*11 were suggested to 
represent protective alleles in early-onset breast cancer 
susceptibility (18). Both these alleles were 
significantly overexpressed in controls (7% and 16.3% 
respectively) as compared to breast cancer patients. In 
another study, a significant increase in the frequency 
of HLA DRB1*04 and HLA DQB1 *02 alleles and a 
decrease in the frequency of HLA DQB1*06 allele 
were reported in hepatocellular carcinoma patients 
(22).  Therefore, we believe that a molecular analysis 
of HLA DRB, DQB and DPB alleles in our local 
patients with CRC and matched healthy controls might 
provide preliminary information to the potential 
existence of alleles that could confer susceptibility or 
resistance to this CRC in the local context. Such an 
approach may contribute an insight on the role of 
immune surveillance in cancer. 
 
 
MATERIALS AND METHODS 
 
SUBJECTS 
 
Ethics approval was obtained from the UKM Research 
Ethics Committee and written informed consent was 
obtained from subjects prior to the collection of blood 
samples. Three milliliters of peripheral blood were 
collected in BD Vacutainer® EDTA Tubes (Becton 
Dickinson) from 42 CRC patients and 50 healthy 
controls who were admitted to UKM Medical Center, 
Kuala Lumpur (UKMMC) from 2012 – 2013. Samples 
from healthy volunteers were used as controls and 
classified as participants who went through endoscopy 
as part of their annual health screening and 
subsequently diagnosed as normal. The CRC patients 
were histologically confirmed, primary-diagnosed and 
did not receive any form of treatment prior to blood 
sample collection. The histological stage of the tumor 
was determined according to the Duke's staging 
system. Data including patient clinical history, age, 
gender, colorectal polyp classification and tumor 
staging are summarized in Table 1. None of the donors 
suffered from allergies or autoimmune diseases and all 
were free from acute or chronic infections. Patients 
who underwent neoadjuvant treatment or resection 
were excluded from the study. 
 
HLA TYPING SEQUENCE BASED TYPING 
(SBT) 
 
Genomic DNA was extracted from peripheral blood 
using a commercial kit (Qiagen DNeasy Blood & 
Tissue Kit). Genotyping of HLA class II loci DRB1, 
DQB1 and DPB1 was performed by a PCR-SBT 
technique using SBT typing kits (AlleSEQR®, Abbot 
Molecular) according to the manufacturer’s protocol. 
Briefly, PCRs were performed in a total volume of 
10µl using 40ng of genomic DNA and reaction 
mixture (Gene-specific PCR Amplification Mix and 
AmpliTaq Gold, Thermo Fisher Scientific Inc., 
Waltham, MA). Samples were denatured at 96°C for 
10 minutes followed by 36 cycles of amplification 
with the annealing temperature of 72°C.  PCR 
products were visualized on a 2% agarose gel. 
Following this, 2 µl of treated PCR product was added 
to 8 µl sequencing mix and treated to another round of 
PCR with an annealing temperature of 50°C, 30 
seconds for 25 cycles. Samples were then treated with 
15 µl HiDi Formamide and sequenced using the 
ABI3130XL genetic analyzer (Applied Biosystems®). 
 
STATISTICAL ANALYSIS 
 
Data analysis was performed using the MedCalc 
Statistical Software. The frequency of HLA DRB1, 
DQB1 and DPB1 in the sample populations was 
determined. Strength of the statistical association 
between sample populations with genetic markers was 
expressed by odds ratio (OR). Statistical significance 
was calculated by Student’s t-test. A p<0.05 was 
considered statistically significant. 
 
 
RESULTS 
 
Genotyping of HLA class II loci DRB1, DQB1 and 
DPB1 was performed by PCR-SBT technique. A 
representative data of PCR-SBT is shown in Figure 1. 
We observed evenly spaced peaks and minimal base 
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Table 1: Demographic and clinical data of CRC patients and controls of this study. 
 
 
 
 
Figure 1: A representative data of PCR-sequence-based typing (SBT) showing evenly spaced peaks and minimal 
baseline noise in all the chromatograms, indicating good quality and strong reliability of the results.   
Patients                     
                                                      Normal ( total =50) CRC (total =42)    
Sex
Male 25 21
Female 25 21
Mean age (year) 60 62
Age range 35-70 37-82
Ethnicity
Chinese 25 22
Malay 20 17
Indian 5 2
Duke's staging
A not related 4
B not related 15
C not related 9
D not related 1
Others not related 12
Number, n
Nor Adzimah Johdi et al.                     Asia Pac. J. Mol. Med 
4 
 
 
 
 
 
 
 
 
Table 2: The distribution of DPB1 alleles in controls and CRC patients.
Normal CRC
(n =50) (n =42)
DPB1 *01:01:01 4 (8%) 1 (2.4%) 0.2642 0.0301 2.6122 0.28
*02:01:02 8 (16%) 16 (38.1%) 0.0189* 1.2131 8.6044 3.23
*02:02:00 5 (10%)   9 (21.4%) 0.1365 0.7528 8.0034 2.45
*03:01:01 5 (10%)   5 (11.9%) 0.7703 0.3269 4.5243 1.22
*04:01:01:01 18 (36%) 17 (40.5%) 0.6597 0.5196 2.8127 1.21
*04:02:01:01 2 (4%) 2 (4.8%) 0.8585 0.1617 8.9061 1.2
*05:01:01 29 (58%) 18 (42.9%) 0.1494 0.2368 1.2455 0.54
*09:01:00 1 (2%) 1 (2.4%) 0.9008 0.0725 19.7071 1.2
*13:01:00 12 (24%)   6 (14.3%) 0.2465 0.1791 1.5554 0.53
*14:01:00 4 (8%) 3 (7.1%) 0.8773 0.1865 4.1954 0.88
*17:01:00 2 (4%) 1 (2.4%) 0.6666 0.0512 6.6919 0.59
*21:01:00 1 (2%) 3 (7.1%) 0.2586 0.3772 37.6689 3.77
*28:01:00 3 (6%) 1 (2.4%) 0.4127 0.0382 3.8175 0.38
CRC=colorectal cancer; CI=confidence interval, OR=odds ratio, *Significant difference (p <0.05)
        HLA allele p  value 95% CI OR
Table 3:  The distribution of DQB1 alleles in controls and CRC patients.
Normal CRC
(n =50) (n =42)
DQB1 *02:01:01   5 (10%)   6 (14.3%) 0.5299 0.4233 5.3156 1.5
*02:02   6 (12%) 2 (4.8%) 0.2352 0.07 1.9219 0.37
*03:01:01:01 24 (48%) 16 (38.1%) 0.3407 0.2895 1.5351 0.67
*03:01:02 1 (2%) 4 (9.5%) 0.1497 0.5536 48.0602 5.16
*03:02:01 2 (4%)   6 (14.3%) 0.1012 0.7623 20.9879 4
*03:03:02:01   8 (16%)   8 (19.0%) 0.7012 0.4198 3.6349 1.24
*04:01:01 1 (2%) 3 (7.1%) 0.2586 0.3772 37.6689 3.77
*04:02:01 4 (8%)   1 (2.38%) 0.2642 0.0301 2.6122 0.28
*05:01:01:01 10 (20%) 4 (9.5%) 0.1721 0.1216 1.4574 0.42
*05:02:01   5 (10%) 12 (28.6%) 0.0278* 1.1502 11.2676 3.6
*05:03:01:01   5 (10%) 3 (7.1%) 0.6296 0.1554 3.0849 0.69
*06:01:01   8 (16%0   7 (16.7%) 0.9313 0.3463 3.1834 1.05
*06:02:01   5 (10%) 1 (2.4%) 0.1744 0.0246 1.9582 0.22
*06:03:01 2 (4%) 1 (2.4%) 0.6666 0.0512 6.6919 0.59
*06:09 1 (2%) 1 (2.4%) 0.9008 0.0725 19.7071 1.2
*06:10 1 (2%) 1 (2.4%) 0.9008 0.0725 19.7071 1.2
*06:35 1 (2%) 1 (2.4%) 0.9008 0.0725 19.7071 1.2
CRC=colorectal cancer; CI=confidence interval, OR=odds ratio, *Significant difference (p <0.05)
       HLA allele p  value 95% CI OR
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Figure 2: Percentage distribution of HLA DPB1*02:01:02 (A) and DQB1*05:02:01 (B) alleles 
according to ethnicity.  
 
Table 4: The distribution of DRB1 alleles in controls and CRC patients.
Normal CRC 
(n =50) (n =42)
DRB1 *01:01:01 2 (4%) 1 (2.4%) 0.6666 0.0512 6.6919 0.59
*03:01:01:01  6 (12%) 4 (9.5%) 0.7044 0.2026 2.9409 0.77
*04:03:01 4 (8%) 2 (4.8%) 0.5353 0.1 3.3072 0.58
*04:05:01 4 (8%)   5 (11.9%) 0.5325 0.3893 6.2033 1.55
*07:01:01:01  9 (18%)   6 (14.3%) 0.6316 0.2463 2.3407 0.76
*08:03:02   1 (2%) 3 (7.1%) 0.2586 0.3772 37.6689 3.77
*09:01:02  5 (10%)   5 (11.9%) 0.7703 0.3269 4.5243 1.22
*10:01:01 3 (6%) 1 (2.4%) 0.4127 0.0382 3.8175 0.38
*11:01:01 4 (8%) 4 (9.5%) 0.7963 0.2837 5.1658 1.21
*12:01:01 2 (4%) 1 (2.4%) 0.6666 0.0512 6.6919 0.59
*12:02:01 17 (34%0 16 (38.1%) 0.6834 0.5083 2.8076 1.2
*13:01:01 2 (4%) 1 (2.4%) 0.6666 0.0512 6.6919 0.59
*14:01:01 3 (6%) 2 (4.8%) 0.7946 0.1246 4.9236 0.78
*14:04 2 (4%) 1 (2.4%) 0.6666 0.0512 6.6919 0.59
*15:01:01:01 13 (26%)   7 (16.7%) 0.2829 0.2035 1.5921 0.57
*15:02:01  9 (18%) 8 (19%) 0.8974 0.3731 3.0795 1.07
*16:02:01 4 (8%)  4 (9.5%) 0.7963 0.2837 5.1658 1.21
CRC=colorectal cancer; CI=confidence interval, OR=odds ratio, †Significant difference (p <0.05)
HLA allele p -value 95% CI OR
A B 
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line noise in all the chromatograms, indicating good 
quality and strong reliability of the results.  
Statistical analysis on the frequency distribution of 
DPB1, DQB1 and DRB1 alleles showed that 
DPB1*02:01:02 and DQB1*05:02:01were 
statistically significant in the sample populations 
(Table 2-4). The frequency of DPB1*02:01:02 allele 
was found to be 38.1% in CRC patients compared to 
16% in healthy controls (p=0.0189, OR=3.23; Table 
2). For the DQB1*05:02:01 allele, frequency of 
distribution was 28.6% in CRC patients and 10% in 
healthy controls (p=0.0278, OR=3.60; Table 3). No 
significant association was found in the samples for 
DRB1 alleles (Table 4).  
Further analysis on DPB1*02:01:02 and 
DQB1*05:02:01 alleles based on frequency 
distribution within ethnicities showed that 
DPB1*02:01:02 allele was detected in 73% of the 
Chinese subjects, 26% in the Malays and 1% in the 
Indians (Figure 2a). As for the DQB1 *05:02:01 allele, 
it was found in 55% of Chinese subjects, 36% in the 
Malays and 9% in the Indians (Figure 2b). Association 
of these two alleles with the patients’ clinical data 
showed that more than 80% of the patients with 
DPB1*02:01:02 and HLA DQB1*05:02:01 alleles 
had Dukes’ A and Dukes’ B CRC. 
 
DISCUSSION 
The inheritance of specific HLA class II genes may 
influence immune responses or confer immunological 
tolerance towards pathogens or tumor antigens. HLA 
class II antigens play a pivotal role in stimulating 
inflammatory responses. Therefore, information on 
polymorphisms of HLA class II alleles may provide a 
better understanding of the roles of these molecules in 
the tumor immunology. This further opens up new 
avenues for immunodiagnostics and strategies in 
immunotherapy. 
In this study, CRC was chosen as a model not only 
because it is one of the commonest cancers in the 
world (1, 2), but also based on the presumption that 
genetic instability that occurs in many CRC cases 
might also affect the genetic structure and effector 
functions of the HLA alleles.  
A significant positive association between the 
DPB1*02:01:02 and DQB1*05:02:01 alleles with 
CRC indicate that the DPB1*02:01:02 and 
DQB1*05:02:01 alleles confer a higher risk of 
developing CRC and a possible role in promoting 
chronic inflammation. Other studies have suggested 
that the HLA-DQB*03032 allele may have a 
protective effect for early-onset breast cancer 
susceptibility (18). The group also suggest that the 
allele could be in linkage disequilibrium with an 
unidentified growth-regulating gene which 
dominantly suppresses mammary tumorigenesis (18). 
Taking that into the CRC context, it could be possible 
that the HLA-DPB1*02:01:02 and DQB1*05:02:01 
alleles are in linkage disequilibrium with a growth-
regulating gene related to CRC such as the hSETD1A 
gene (33), PTTG gene (34, 35) or TGFBR2 (36). 
These polymorphic alleles may dominantly enhance 
the CRC tumorigenesis. However, further validation 
of the significance of these two HLA alleles is needed 
in a bigger sample size and functional analysis is 
crucial to support this hypothesis.  
A significant association between CRC with the DRB1 
allele was not observed in this study in contrary to 
many reports in other studies (18, 25, 29, 32). This 
could due to a limitation in sample size.  
In conclusion, we identified the DPB1*02:01:02 and 
DQB1*05:02:01 alleles as possible risk factors for 
CRC. More studies need to be conducted to investigate 
the possible association and roles of these alleles with 
CRC. The positive association noted for 
DPB1*02:01:02 and DQB1*05:02:01 warrants 
validation in larger numbers of CRC patients. 
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